The effect of complement on transgene expression was evaluated in vivo and in vitro using mice lacking complement components. Complement component 3 (C3) deficient mice (C3
Activation of innate immunity and promotion of inflammation are common responses to replication incompetent adenoviruses (Ad) now being developed as vectors for gene therapy. 1, 2 The complement system is central to both innate immunity and inflammation. 3, 4 As it is comprised of multiple membrane-bound and bloodborne factors, the complement system is probably of particular relevance in delivery of vectors administered intravenously. In fact, Cichon et al 5 showed that complement was activated in a majority of human plasma samples when challenged with different adenoviral serotypes; complement activation was completely dependent on anti-Ad antibody. Based on these studies, the suggestion was made that complement activation would not be a problem for local delivery of low Ad doses, but high doses of Ad administered by a systemic route could have potentially adverse consequences. 5 Complement 'activation' is a complex series of enzymatic reactions that converts pre-existing protein substrates into biologically active end-products. For example, in a process called opsonization, the deposition of C3 fragments onto pathogens promotes the removal of the pathogens by the reticuloendothelial system. In gene therapy applications, redirection of the vector in this manner might lead to toxicity. Equally important, less vector would remain available for transfecting the desired target cell population. Consistent with this view, Wilson et al reported greater reporter expression in mouse hepatocytes following systemic Ad administration with high vector doses that saturated Kupffer cells. 6 This was true even with doses that included a different Ad without the reporter construct. 6 It is widely accepted that the liver is the predominant site of reporter gene expression following intravenous injection of wild-type Ad5 vectors. 7 Coxsackie and adenovirus receptor (CAR), integrins, and heparin sulfate proteoglycans have all been shown to be important for liver transfection. [7] [8] [9] [10] [11] [12] Ad vectors with CAR binding site mutations and ablation of integrin-binding showed less luciferase expression in liver following systemic administration. 7 Similarly, ablation of CAR-binding via short fiber replacements also lead to reduced liver tropism.
11
More recently it was reported that blood coagulation factor IX was also involved in liver transduction. 13 The humoral immune response also influences liver transgene expression, especially when the host is repeatedly exposed to the vector, because neutralizing antibody can diminish liver transfection.
The data reported herein show for the first time the importance of complement in the transduction of mouse liver by Ad. To directly address the role of complement in liver transduction, we performed studies using wildtype mice versus mutant mice unable to make complement component 3 (C3).
14 By repeated bioluminescence imaging of living mice, we assessed liver luciferase expression following intravenous delivery of the Ad vector. Surprisingly, at low Ad5Luc1 doses, C3 deficient mice (C3 À/À ) showed up to 99-fold less luciferase expression in the liver compared to wild-type controls, indicating a facilitatory role for the complement pathway in liver transduction. The current experiments used C3 À/À mice with the C57BL/6 background, together with littermate controls (homozygous C3 +/+ ), matched for sex and age (hereafter, wild type or control).
In Figure 1 we present representative images captured from mice that received the lowest dose (2.3 Â 10 9 v.p.) of Ad5Luc1. Each image (1-min acquisition) was collected on day 13 after Ad5Luc1 delivery; the pseduocolor overlay represents the intensity of light emission, and thus the level of luciferase expression. Overall, wild-type mice showed 12.7-fold greater liver luciferase expression than C3 À/À mice at this time point, and the absolute difference was statistically significant (Po0.05, ANOVA). 15 With all three doses of Ad5Luc1, peak liver luciferase expression in both kinds of mice was detected on days 6-10 ( Figure 2 ). Maximal luciferase expression ranged from 10-to 100-times greater than that observed 1-2 days after vector administration. Wild-type mice always showed higher liver luciferase expression, but the absolute difference between wild-type and C3 À/À mice was diminished as the dose of Ad5Luc1 was increased. For example, liver luciferase expression 3 days after injection of 2.3 Â 10 9 v.p. was 99-fold higher in wild-type mice compared to C3 À/À mice ( Figure 2a ). For mice injected with 4.0 Â 10 9 v.p. (Figure 2b ), wild-type mice showed 35-fold higher liver luciferase expression compared to C3 À/À mice. For the highest Ad5Luc1 dose (1.3 Â 10 10 v.p.), the maximal difference between the two groups was 3.4-fold (Figure 2c ). For the C3 À/À mice in isolation, significantly greater luciferase expression in the liver was observed with increasing Ad5Luc1 vector dose. In contrast, the control mice with an intact complement , and 1.3 Â 10 10 v.p.). At various times after administration of Ad5Luc1, the mice were imaged using a bioluminescence imaging system (Xenogen, Inc.) to detect luciferase expression. Images were collected on mice oriented in the same position and always 10 min after intraperitoneal injection of 2.5 mg luciferin. The mice were maintained under enflurane anesthesia at 371C, with their ventral surfaces facing the CCD camera that was part of the imaging system. Imaging was performed several times on each mouse, beginning at 6 h after Ad5Luc1 injection and continuing to day 34. Data acquisition times for imaging ranged from 20 s to 10 min.
Complement and
An experiment was performed in the two groups of mice using intravenous Ad5FFLuc1 (4.0 Â 10 9 v.p.). Ad5-FFLuc1 is a fibritin-fiber Ad5 encoding Luc1 and does not support CAR-dependent pathways of infection. 16 As shown in Figure 3 , the wild-type mice averaged higher levels of liver luciferase expression compared with C3
À/À mice; maximal difference was 22-fold at 17 days after injection. These data suggest the complement effect on liver transfection is independent of CAR-mediated mechanisms.
Complement appeared to facilitate liver transduction as C3
À/À mice always showed lower luciferase expression than wild-type mice. The facilitation effect was overcome if high numbers of the vector were injected, thus C3
À/À and wild-type mice showed similar liver luciferase expression after administration of 1.3 Â 10 10 Ad5Luc1. Importantly, none of the mice used in the present study were previously exposed to Ad vectors, so the complement-dependent effect was independent of an antibody response against the Ad vector. Also, the complement-dependent effect did not require CARdependent routes of infection, as demonstrated using Ad5FFLuc1. À/À group for that time point, with the '*' indicating statistical significance at Po0.05. Each line is representative of four mice, except there were only three control mice in (b). Male mice (a) and female mice (b-c) were used. Light emission from the liver region (relative photons/s) was measured using software provided by Xenogen, and the intensity represents the liver luciferase activity. This relationship was validated by comparing luciferase measurements from the live animals with independent measurements obtained from tissue homogenates as described. 30 These comparisons were accomplished at termination by removal of liver and spleen (mice injected with 2.3 Â 10 9 v.p.), followed by independent in vitro luciferase analyses as described. The validation also confirmed that the liver was responsible for 499% of the light emission that was detected in the liver region of the live mice using the Xenogen system. 
, or C3
À/À ), PBS, or a mixture of wild type and C3 À/À sera. Each mixture was diluted (3 ml) and 0.3 ml was incubated for 1 h with adherent TIB76 cells in 24-well plates. Luciferase and protein assays were conducted after 22 h. Different letters indicate statistically significant differences in treatments at Po0.05. These data are from one experiment, but are representative of data from experiments repeated on three different days.
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Complement activation may lead to opsonization of the vector, binding of the complement-coated vector to cells, and subsequent infection. To test this hypothesis, in vitro studies were conducted with Ad5Luc1 and fresh serum from transgenic mice lacking complement components. Mouse liver hepatoma (TIB76) cells were incubated with the Ad5Luc1 following preincubation for 5 min with the various sera. As shown in Figure 4 , preincubation of Ad5Luc1 with C3 À/À sera resulted in luciferase levels in the TIB76 cells that were not significantly different from levels in TIB76 cells treated with Ad5Luc1 preincubated with PBS. Importantly, preincubation of Ad5Luc1 with C3 À/À serum resulted in significantly less (Po0.05) luciferase expression (threefold) compared to preincubation with wild-type serum. Remarkably, preincubation with C1q À/À and FB À/À sera achieved intermediate levels of transduction in the TIB76 cells.
Our in vitro and in vivo findings suggest that C3, and likely its activation via either a FB-or C1q-dependant pathway, enhances Ad5 mediated transduction of the liver or liver cells. It appears that opsonization of the Ad5 particle itself facilitates transfection, which would point to a potential cellular complement receptor as another important component of this mechanism. While the current work does not identify this receptor, it provides strong evidence for its existence. Of interest, it was recently reported that group B adenovirus uses CD46, a complement regulatory protein, for cellular attachment. 17 Therefore, the current report provides another example of an adenovirus exploiting a complement pathway for infection. As such, a strong immune response may be a consequence. This is in contrast to other pathways by which pathogens exploit the complement system as a means to escape the host immune response. [18] [19] [20] [21] [22] [23] For example, HIV has evolved to exploit complement pathways to survive and promote transmission to permissive cells. 24 In order for systemic delivery of Ad vectors to achieve clinical practicality, a better understanding of innate immunity is needed, including how complement influences the transduction process. Our findings suggest that inhibition of complement may be a valid approach to overcome the liver's propensity to remove systemically administered Ad, as well as an approach to reduce the strong immune response to the Ad vector. Two reports from another group are supportive of this concept, as complement depletion improved intravascular delivery of replication-conditional Herpes virus to human xenograft tumors growing in rat brain. 25, 26 While Ikeda et al utilized a different virus and model system, their findings of improved delivery of virus to the brain xenografts following complement inhibition is consistent with reduced opsonization and reduced liver sequestration. Less inactivation and removal of virus would make more available to target the xenograft brain tumors. In addition to benefits for tumor targeting, inhibition of complement activation may also have the added benefit of decreasing the humoral and cell mediated immune response to virus. 27 It is envisioned that future Ad vectors will display complement regulatory proteins on their surface, or other surface proteins capable of binding negative regulators of complement activation in host blood. Potential sites of incorporation of these proteins in the Ad include the hexon, or pIX, a recently demonstrated site for genetic addition of peptides. 28 A linker site (poly GGGGS) between the FF chimera and retargeting ligands is another potential site. 16 In this manner, negative regulators of complement activation would be present on the surfaces of the Ad vector. Complement activation would thereby be reduced, potentially minimizing undesired toxicities (inflammation, immune response) and/or improving targeting outcomes to tissues other than liver. In combination with other efforts to modify the vector for targeting, efforts to interfere with complement should be considered.
